| Literature DB >> 19379482 |
Judith C Booij1, Simone van Soest, Sigrid M A Swagemakers, Anke H W Essing, Annemieke J M H Verkerk, Peter J van der Spek, Theo G M F Gorgels, Arthur A B Bergen.
Abstract
BACKGROUND: To determine level, variability and functional annotation of gene expression of the human retinal pigment epithelium (RPE), the key tissue involved in retinal diseases like age-related macular degeneration and retinitis pigmentosa. Macular RPE cells from six selected healthy human donor eyes (aged 63-78 years) were laser dissected and used for 22k microarray studies (Agilent technologies). Data were analyzed with Rosetta Resolver, the web tool DAVID and Ingenuity software.Entities:
Mesh:
Year: 2009 PMID: 19379482 PMCID: PMC2679759 DOI: 10.1186/1471-2164-10-164
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Figure 1Distribution of the mean intensity (μ. Each bin contains 2,194 genes. Note that the mean expression level associated with the 100th percentile bin is not displayed fully in this graph due to the height of the expression exceeding the scope of the graph.
Overrepresented Kegg pathways in macular RPE expressed genes with high, moderate and low expression levels and high or low levels of interindividual variability (coefficient of variation, CV).
| expression level | |||||
| all expression levels | high (> 90th perc) | moderate (50th–90th perc) | low (10th–50th perc) | ||
| all CV | ecm-receptor interaction (E) | oxidative phosphorylation (B,E) | phosphatidylinositol signaling system (B,E) | neuroactive ligand receptor interaction (B,E) | |
| CV | high CV | type I diabetes mellitus (B,E) | antigen processing and presentation (B,E) | focal adhesion (E) | type I diabetes mellitus (E) |
| low CV | - | glycosaminoglycan degradation (E) | - | - | |
Overrepresented pathways were identified with B: a Benjamini-Hochberg corrected p value < 0.001, or E: an Ease score p value < 0.001. Perc: percentile, high CV: > 90th percentile, low CV: < 10th percentile.
Figure 2Ingenuity analysis of the cross section of genes previously identified in RPE studies[14]with genes highly expressed in the RPE transcriptome. The resulting network shows a connectivity chart illustrating biological functions comprising genes, proteins and ligands related to cell-cell signaling and cell-cell interaction. This network contains 13 of the 16 genes entered into the analysis. Filled objects represent the genes entered, empty objects are genes introduced by the ingenuity software creating a connection between the entered genes.
The thirty most highly expressed genes in macular RPE identified in six different human donors, sorted by intensity in descending order.
| gene symbol | Genbank ID | mean intensity μint perc | CV perc | gene name | relevant function |
| 99 | 98 | KIAA0241 | |||
| 99 | 98 | Transcribed locus | |||
| 99 | 98 | ACN9 homolog | gluconeogenesis [ | ||
| 99 | 98 | Metallothionein 1A | protection against reactive oxygen species[ | ||
| 99 | 98 | Solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 7 | glutamate transporter, expressed in RPE[ | ||
| 99 | 98 | Tumor protein p53 | protection against reactive oxygen species[ | ||
| 99 | 98 | E74-like factor 2 (ets domain transcription factor) | |||
| 99 | 95 | cDNA clone | |||
| 99 | 79 | cDNA clone | |||
| 99 | 98 | Serpin peptidase inhibitor, clade B, member 5 | |||
| 99 | 97 | minichromosome maintenance deficient 7 | |||
| 99 | 96 | Solute carrier family 1 member 2 | glutamate transporter[ | ||
| 99 | 99 | Hemoglobin, beta | |||
| 99 | 94 | Prostaglandin D2 synthase 21 kDa | released from RPE during rod phagocytosis [ | ||
| 99 | 75 | cDNA clone | |||
| 99 | 80 | Eukaryotic translation elongation factor 1 alpha 1 | |||
| 99 | 80 | Transthyretin (prealbumin, amyloidosis type I) | maintains normal levels of retinol and retinol binding proteins in plasma [ | ||
| 99 | 90 | cDNA clone | |||
| 99 | 92 | Cystatin C | associated with AMD[ | ||
| 99 | 95 | Zinc finger protein 503 | |||
| 99 | 94 | cDNA clone | |||
| 99 | 80 | cDNA clone | |||
| 99 | 94 | Heat shock protein 90 kDa beta (Grp94), member 1 | [ | ||
| 99 | 90 | Guanine nucleotide binding protein (G protein), gamma transducing activity polypeptide 1 | |||
| 99 | 20 | Ribosomal protein L3 | |||
| 99 | 23 | Ribosomal protein L41 | |||
| 99 | 77 | cDNA clone | |||
| 99 | 90 | Proprotein convertase subtilisin/kexin type 7 | |||
| 99 | 75 | cDNA clone | |||
| 99 | 42 | Clusterin | member of complement system [ | ||
Among these genes we identified five genes with known expression in the RPE (SLC17A7[14], CST3[18], TTR[14], HSP90B1[21] and PTGDS[17]). The SLC17A7 gene is a glutamate transporter, like the SLC1A2 gene which is also in the top 30 highly expressed genes. The CST3 gene was previously suggested to have an association with AMD[16,17]. The list also contains two genes with a role in the protection against oxidative stress (MT1A[22], TP53[23]). The GNGT1 gene, expressed in photoreceptors[30], suggests the inevitable presence of photoreceptor contamination. Perc: percentile.
The top thirty genes with the highest interindividual variation in expression levels (CV) between six healthy human donors, sorted descending by coefficient of variation (CV).
| gene symbol | Genbank ID | mean intensity μint perc | CV perc | gene name |
| 95 | 99 | Hydroxysteroid (17-beta) dehydrogenase 2 | ||
| 99 | 99 | Myocilin, trabecular meshwork inducible glucocorticoid response | ||
| 92 | 99 | Osteoglycin (osteoinductive factor, mimecan) | ||
| 93 | 99 | Secreted frizzled-related protein 4 | ||
| 91 | 99 | Amine oxidase, copper containing 2 (retina-specific) | ||
| 85 | 99 | Deiodinase, iodothyronine, type III | ||
| 62 | 99 | Solute carrier family 2 (facilitated glucose/fructose transporter), member 5 | ||
| AK025198 | 99 | 99 | X (inactive)-specific transcript | |
| 99 | 99 | Tissue factor pathway inhibitor 2 | ||
| 98 | 99 | Cysteine-rich, angiogenic inducer, 61 | ||
| 84 | 99 | Ksp37 protein | ||
| 64 | 99 | Fructose-1,6-bisphosphatase 2 | ||
| 74 | 99 | EGF-like-domain, multiple 6 | ||
| 66 | 99 | Interleukin 8 | ||
| L38486 | 99 | 99 | Microfibrillar-associated protein 4 | |
| 90 | 99 | Chemokine (C-C motif) ligand 2 | ||
| 67 | 99 | Zinc family member 1 (odd-paired homolog, Drosophila) | ||
| 88 | 99 | Collagen, type IX, alpha 1 | ||
| 79 | 99 | Chemokine (C-C motif) ligand 26 | ||
| 89 | 99 | Paired-like homeodomain transcription factor 2 | ||
| 78 | 99 | Aldehyde dehydrogenase 1 family, member A1 | ||
| 75 | 99 | Hemoglobin, gamma A | ||
| 99 | 99 | S100 calcium binding protein A6 | ||
| 77 | 99 | Interleukin 6 (interferon, beta 2) | ||
| 71 | 99 | Hemoglobin, gamma G | ||
| 93 | 99 | Chromosome 13 open reading frame 33 | ||
| 96 | 99 | RNA binding motif (RNP1, RRM) protein 3 | ||
| 94 | 99 | Complement factor B | ||
| 99 | 99 | Early growth response 1 | ||
| 97 | 99 | Pentraxin-related gene, rapidly induced by IL-1 beta | ||
Note that although XIST, EGFL6 and RBM3 are x-chromosomal transcripts, their high interindividual variation could not be explained by the gender of the donors (data not shown). Perc: percentile.
The thirty genes with the least interindividual variation in macular RPE gene expression levels among six healthy human donors, sorted ascending by coefficient of variation (CV).
| gene symbol | Genbank ID | mean intensity μint perc | CV perc | gene name |
| 85 | < 1 | Exocyst complex component 3 | ||
| 74 | < 1 | Pyridoxal (pyridoxine, vitamin B6) kinase | ||
| 63 | < 1 | Aminoacylase 1 | ||
| 70 | < 1 | Synovial sarcoma translocation gene on chromosome 18-like 1 | ||
| 86 | < 1 | FOS-like antigen 1 | ||
| 56 | < 1 | Formyl peptide receptor-like 2 | ||
| 62 | < 1 | Cleavage and polyadenylation specific factor 4, 30 kDa | ||
| 40 | < 1 | Chromosome 8 open reading frame 72 | ||
| 20 | < 1 | Transcribed locus | ||
| 15 | < 1 | Chromodomain helicase DNA binding protein 2 | ||
| 20 | < 1 | Transcribed locus | ||
| 37 | < 1 | Fetal and adult testis expressed 1 | ||
| 44 | < 1 | C-type lectin domain family 4, member E | ||
| 75 | < 1 | Poly(A)-specific ribonuclease (deadenylation nuclease) | ||
| 59 | < 1 | KIAA0586 | ||
| 41 | < 1 | Transmembrane protein 156 | ||
| 59 | < 1 | Casein kinase 2, alpha 1 polypeptide | ||
| 35 | < 1 | CGI-96 protein | ||
| 26 | < 1 | Transcribed locus | ||
| 93 | < 1 | MYST histone acetyltransferase (monocytic leukemia) 3 | ||
| 33 | < 1 | Protein kinase C binding protein 1 | ||
| 88 | < 1 | Chromosome 20 open reading frame 11 | ||
| 89 | < 1 | Cyclin G associated kinase | ||
| 67 | < 1 | hypothetical protein FLJ10159 | ||
| 16 | < 1 | Zinc finger protein 665 | ||
| 57 | < 1 | cDNA clone | ||
| 57 | < 1 | Olfactory receptor, family 2, subfamily A, member 7 | ||
| 18 | <1 | Protein kinase C, epsilon | ||
| 88 | < 1 | Ring finger protein 14 | ||
| 93 | < 1 | Selenium binding protein 1 | ||
Perc: percentile.
Expression levels and interindividual differences of currently known macular disease genes with RPE expression[26].
| 10,382 | (94) | 215 | (99) | ||
| 9,910 | (94) | 145 | (98) | ||
| 2,823 | (76) | 136 | (98) | ||
| 32,204 | (98) | 86 | (93) | ||
| 2,329 | (72) | 83 | (93) | ||
| 338 | (26) | 79 | (92) | ||
| 8,508 | (92) | 77 | (91) | ||
| 7,209 | (91) | 73 | (90) | ||
| 1,689 | (65) | 71 | (90) | ||
| 132,611 | (99) | 58 | (84) | ||
| 45,420 | (99) | 47 | (74) | ||
| 20,292 | (97) | 44 | (70) | ||
| 23,226 | (98) | 40 | (64) | ||
| 225 | (45) | 38 | (60) | ||
| none | - | - | - | ||
Data are grouped by coefficient of variation (CV) in descending order into three groups, high CV (> 90th percentile, CV > 72), intermediate (CV 10th – 90th percentile) and low CV (< 10th percentile, CV < 19). Perc: percentile.
Expression levels and interindividual differences of currently known peripheral disease genes with RPE expression[26].
| 5,628 | (88) | 225 | (100) | ||
| 20,291 | (97) | 196 | (100) | ||
| 527 | (37) | 122 | (97) | ||
| 100,271 | (100) | 80 | (92) | ||
| 6,716 | (90) | 78 | (92) | ||
| 43,011 | (99) | 74 | (91) | ||
| 46,964 | (99) | 66 | (88) | ||
| 2,672 | (75) | 64 | (87) | ||
| 3,266 | (79) | 63 | (86) | ||
| 12,177 | (95) | 63 | (86) | ||
| 15,935 | (96) | 62 | (86) | ||
| 519 | (37) | 62 | (86) | ||
| 11,010 | (95) | 61 | (86) | ||
| 39,454 | (99) | 57 | (83) | ||
| 6,284 | (89) | 57 | (83) | ||
| 7,168 | (91) | 56 | (82) | ||
| 2,824 | (76) | 54 | (80) | ||
| 4,473 | (84) | 51 | (78) | ||
| 273 | (20) | 48 | (75) | ||
| 1,734 | (65) | 48 | (75) | ||
| 3,762 | (81) | 45 | (71) | ||
| 9,589 | (93) | 45 | (71) | ||
| 1,556 | (63) | 45 | (71) | ||
| 6,510 | (90) | 40 | (64) | ||
| 913 | (50) | 39 | (63) | ||
| 7,964 | (92) | 39 | (62) | ||
| 20,540 | (97) | 39 | (62) | ||
| 911 | (50) | 38 | (61) | ||
| 12,114 | (95) | 37 | (59) | ||
| 5,411 | (87) | 37 | (58) | ||
| 1,394 | (60) | 35 | (53) | ||
| 6,691 | (90) | 34 | (53) | ||
| 4,446 | (84) | 34 | (51) | ||
| 2,946 | (77) | 33 | (50) | ||
| 3,750 | (81) | 32 | (46) | ||
| 372 | (28) | 32 | (45) | ||
| 1,555 | (63) | 28 | (35) | ||
| 4,763 | (85) | 28 | (35) | ||
| 1,023 | (53) | 28 | (34) | ||
| 13,200 | (96) | 27 | (33) | ||
| 5,341 | (87) | 25 | (25) | ||
| 962 | (51) | 23 | (20) | ||
| 2,056 | (69) | 22 | (16) | ||
| 1,335 | (59) | 20 | (14) | ||
| 3,293 | (79) | 20 | (12) | ||
| 4,935 | (86) | 19 | (10) | ||
| 3,187 | (78) | 17 | (06) | ||
| 3,008 | (77) | 15 | (04) | ||
| 7,057 | (91) | 14 | (03) | ||
| 2,277 | (71) | 13 | (02) | ||
| 2,330 | (72) | 8 | (0) | ||
Data are grouped by coefficient of variation (CV) in descending order into three groups, high CV (> 90th percentile, CV > 72), an intermediate group (CV 10th – 90th percentile) and CV low (< 10th percentile, CV < 19).
Figure 3Flow diagram of criteria used for the selection of donor eyes. Donor eyes were required to meet all selection criteria before inclusion in the study. X indicates exclusion from the study. Donors were all between 60 and 80 years old in order to exclude the presence of undetected monogenic disorders. The presence of any known eye disease or malignancy was used as an exclusion criterion since both can alter (RPE) gene expression levels. Post mortem times were required to be less than 30 hours to reduce the effects of RNA degradation. Ocular abnormalities on visual or histological inspection served as exclusion criteria, specifically any signs of early AMD, defined by us as the presence of more than 1 druse per 10 histological sections. Poor morphology of the retina was also an exclusion criterion.
Figure 4Study design. A. Experimental setup. Six RPE samples from 6 different donors were hybridized to six microarrays along with the common reference sample. B. Data analysis. The common reference was used to normalize the RPE expression data from the six arrays which enabled comparison of the six individuals.